ASX Release

BOARDROOM RADIO BROADCAST

PERTH, AUSTRALIA – 8 November 2018: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, provides the opportunity to listen to an audio broadcast with Mr David Phillips, director of SUDA and Mr Andrew Curtis Vice President, Business Development & Alliance Management.

The presentation provides an overview of the exclusive agreement signed with Strides Pharma Global Pte Ltd announced earlier today and also Andrew provides an overview of SUDA’s US strategy.

You may access this webcast at:
https://www.boardroom.media/broadcast?eid=5be276d507564669ff2222d9

Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER/MANAGING DIRECTOR
SUDA Pharmaceuticals Ltd
Tel: +61 8 6142 555
sjcarter@sudapharma.com

NOTES TO EDITORS:
About SUDA Pharmaceuticals Ltd
SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA’s product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com